Intellia Therapeutics reported operational highlights and financial results for the third quarter ended September 30, 2024.
John Leonard MD, Intellia President and Chief Executive Officer, said: “Our third quarter and recent period have been marked by outstanding progress in advancing our pipeline of CRISPR-based gene editing therapies. A key achievement was the initiation of the HAELO Phase 3 study, which we believe will demonstrate what we’ve seen in the first-in-human study — a one-time treatment of NTLA-2002 has the potential to be a functional cure for hereditary angioedema.”

(Source: Intellia)